

MOL #29926

Modulating the Folding of P-glycoprotein and CFTR Truncation Mutants with Pharmacological Chaperones

Ying Wang, Tip W. Loo, M. Claire Bartlett and David M. Clarke

Department of Medicine and Department of Biochemistry, University of Toronto, Toronto,
Ontario, M5S 1A8, Canada

MOL #29926

Running Title: Correction of CFTR and P-gp Topologies

Corresponding Author:

David M. Clarke

Department of Medicine

University of Toronto

Rm. 7342, 1 King's College Circle

Toronto, Ontario, M5S 1A8. CANADA

Tel: 416-978-1105

FAX: 416-978-1105

E-mail: david.clarke@utoronto.ca

Number of text pages: 30

Number of tables: 0

Number of figures: 7

Number of references: 40

Number of words in Abstract: 249

Number of words in Introduction: 570

Number of words in Discussion: 1269

ABBREVIATIONS: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; P-gp, P-glycoprotein; TM, transmembrane; TMD, transmembrane domain; NBD, nucleotide-binding domain.

MOL #29926

ABSTRACT

CFTR and P-glycoprotein (P-gp) are ABC transporters that have two transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs). Defective folding of CFTR lacking phenylalanine 508 (Δ F508) in NBD1 is the most common cause of cystic fibrosis. The F508 position appears to be universally important in ABC transporters because deletion of the equivalent residue (Y490) in P-gp also inhibits maturation of the protein. The pharmacological chaperone VRT-325 can repair the Δ F508-type folding defects in P-gp or CFTR. VRT-325 may repair the folding defects by promoting dimerization of the two NBDs or by promoting folding of the TMDs. To distinguish between these two mechanisms, we tested the ability of VRT-325 to promote folding of truncation mutants lacking one or both NBDs. Sensitivity to glycosidases was used as an indirect indicator of folding. It was found that VRT-325 could promote maturation of truncation mutants lacking NBD2. Truncation mutants of CFTR or P-gp lacking both NBDs showed deficiencies in core-glycosylation that could be partially reversed by carrying out expression in the presence of VRT-325. The results show that dimerization of the two NBDs to form a 'nucleotide-sandwich' structure or NBD interactions with the TMDs are not essential for VRT-325 enhancement of folding. Instead, VRT-325 can promote folding of the TMDs alone. The ability of VRT-325 to promote core-glycosylation of the NBD-less truncation mutants suggests that one mechanism whereby the compound enhances folding is by promoting proper insertion of TM segments attached to the glycosylated loops so that they adopt an orientation favorable for glycosylation.

MOL #29926

Introduction

Cystic fibrosis (CF) is a lethal inherited disorder caused by mutations in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) (Riordan et al., 1989). CFTR is a cAMP-activated chloride channel located on the apical surface of epithelial cells where it helps to regulate salt and fluid transport. The lack of functional CFTR in the lung is currently the most serious problem for CF patients as it contributes to lung failure due to chronic inflammation. The most common CF-associated mutation that is found on at least one chromosome of about 90% of affected individuals is the deletion of phenylalanine 508 in the first nucleotide-binding domain (NBD1) of CFTR (Bobadilla et al., 2002). Little of the $\Delta F508$ CFTR protein is properly delivered to the cell surface because the protein is defective in folding (Chen et al., 2000) and the protein is rapidly degraded (Cheng et al., 1990). The F508 position is also important for folding of other ATP-binding cassette transporters as deletion of the equivalent residue in human P-glycoprotein (P-gp) ($\Delta Y490$) also causes defective folding of P-gp and rapid degradation (Hoof et al., 1994).

A clinical goal in CF research is to develop a drug rescue approach to specifically rescue CFTR mutants with folding defects such as $\Delta F508$ CFTR. The feasibility of a drug-rescue approach was first demonstrated using the $\Delta Y490$ P-gp model system (Loo and Clarke, 1997). Expression of $\Delta Y490$ P-gp in the presence of drug substrates was found to promote maturation of the mutant to yield a functional transporter at the cell surface. Therefore, high-throughput screening of chemical libraries was performed to identify correctors (pharmacological chaperones) that could promote folding of $\Delta F508$ CFTR (Pedemonte et al., 2005; Van Goor et al., 2006). Some correctors were relatively specific for rescue of $\Delta F508$ CFTR. For example, corr-4a is a bisaminomethyl bithiazole compound that promotes maturation of $\Delta F508$ CFTR but

MOL #29926

shows little rescue of a mutant dopamine receptor 4 (Pedemonte et al., 2005) while the thiazole derivative corr-2b and the pyrazole derivative VRT-532 also promote maturation of Δ F508 CFTR but show little or no rescue of a P-gp processing mutant (Wang et al., 2006). An interesting corrector is the quinazoline derivative VRT-325 that can promote maturation of both P-gp and CFTR processing mutants (Loo et al., 2005).

The mechanism of how correctors like VRT-325 promote folding of CFTR and P-gp processing mutants is unknown. One possibility is that correctors interact with the NBDs to promote native interactions between NBD1 and NBD2 so that they form the characteristic ‘nucleotide-sandwich dimer’ structure of ABC transporters (Smith et al., 2002). Although the Δ F508 mutation has little effect on the structure, stability or folding of NBD1 (Lewis et al., 2005), it impairs NBD1-NBD2 interactions and vectorial folding of NBD2 (Du et al., 2005). A second possible mechanism of correctors is that they promote folding of the transmembrane domains (TMDs). It has been found that both the Δ F508-type CFTR (Chen et al., 2004) and P-gp (Loo et al., 2002) mutants have altered packing of the transmembrane (TM) segments. To distinguish between these two mechanisms of corrector action, we constructed P-gp and CFTR deletion mutants lacking one or both of the NBDs. The truncation mutants were then tested to see if the removal of NBD2 would inhibit corrector-induced folding (favor the NBD1-NBD2 interaction model) or whether the folding of mutants lacking one or both NBDs could still be modulated by correctors (favor the TMD folding mechanism).

MOL #29926

Materials and Methods

Construction of Mutants. The construction of Δ F508 CFTR and G268V P-gp cDNAs was described previously (Loo et al., 2005). The CFTR cDNAs coding for Δ NBD2 CFTR (residues 1-1196), the NH₂-terminal half-molecule (N-half CFTR) (residues 1-836), COOH-terminal half-molecule (C-half CFTR) (residues 837-1480) or TMD1+2 (TMD1+2 CFTR) (residues 1-438 plus 838-1178) were modified to contain the epitope tag for monoclonal antibody A52 at the COOH-terminal end of the protein and inserted into the pMT21 expression vector. The P-gp truncation mutants Δ NBD2 P-gp (residues 1-1023), TMD1+2 P-gp (residues 1-379 plus 681-1025), TMD1 P-gp (residues 1-379), N-half P-gp (residues 1-682), and C-half P-gp (residues 681-1278) containing the E875C mutation were constructed as described previously (Loo and Clarke, 1999a; Loo and Clarke, 1999b). The truncation mutants contained the A52 epitope at their COOH-terminal ends.

Expression of Mutants. HEK 293 cells were transfected with the cDNAs as described previously (Loo et al., 2006c). To test for the effect of compounds on expression of CFTR or P-gp processing mutants, cells were grown for 24h in Dulbecco's modification of Eagle's medium (DMEM) with 2% (v/v) calf serum and 0.1 mM non-essential amino acids at 37 °C in a 5% CO₂ incubator in the presence of 10 μ M VRT-325, corr-4a, curcumin, thapsigargin, cyclosporin A or 250 μ M 7,8-benzoquinoline or 100 μ M miglustat. Compounds were prepared as 1000 X stocks in DMSO. Control cells were incubated in the presence of 0.1 % (v/v) DMSO. Cells were harvested and solubilized with 2 X SDS sample buffer (125 mM Tris-HCl, pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS and 4% (v/v) 2-mercaptoethanol) containing 50 mM EDTA, 1 mM AEBSF, 10 μ M E-64, 2 mM benzamidine, 2 μ g/ml aprotinin and 20 μ M leupeptin. Samples were then subjected to SDS-PAGE (5.5% acrylamide gels for full-length P-gp or CFTR) and

MOL #29926

immunoblot analysis with rabbit polyclonal antibody against CFTR or P-gp or with mouse monoclonal antibody A52.

For treatment with endoglycosidase H, a one-tenth volume of 0.5 M sodium citrate, pH 5.5 was added to the solubilized cells followed by addition of 20,000 U/ml of endoglycosidase H (New England Biolabs, Mississauga, ON). The sample was treated for 15 min at 20 °C. For treatment with peptide N-glycosidase F (PNGase F), a one-tenth volume of 0.5 M sodium phosphate, pH 7.5, and one-tenth volume of 10% (v/v) Nonidet P-40 were added to cell extract followed by addition of 10,000 U/ml PNGase F (New England Biolabs). Samples were incubated for 15 min at 37 °C and then subjected to immunoblot analysis as described above.

Cell surface labeling. Cell surface labeling of Δ NBD2/Q1071P CFTR was performed as described previously (Loo et al., 2006c). Briefly, cell surface carbohydrate was oxidized with sodium periodate and then labeled with biotin-LC-hydrazide. The cells were solubilized with 1% (w/v) Triton X-100 and biotinylated CFTR recovered with monoclonal antibody A52. Samples were subjected to immunoblot analysis using streptavidin-conjugated horseradish peroxidase.

Disulfide cross-linking analysis. P-gp mutant L339C (TM6)/F728C (TM7) was transiently expressed in HEK 293 cells (25 10-cm plates). The cells were harvested, washed three times with PBS and membranes were prepared. The membranes were suspended in 0.3 ml TBS, pH 7.4 and preincubated for 15 min at 22 °C in the presence of 10 μ M or 100 μ M corr-2b, corr-3a, corr-4a, VRT-532 or VRT-325 or no drug. Samples were then cross-linked by incubation with 0.2 mM of the methanethiosulfonate (MTS) cross-linker, 3,6,9,12-tetraoxatetradecane-1,14-diyl bismethanethiosulfonate (M14M, 2.08 nm spacer arm) (Toronto Research Chemicals, Downsview, ON, Canada) for 3 min on ice. The cross-linking reactions were stopped by addition of 2 X SDS sample buffer (125 mM Tris-HCl, pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS

MOL #29926

containing 50 mM EDTA and no reducing agent. The reaction mixtures were then subjected to SDS-PAGE (7.5% polyacrylamide gels) and immunoblot analysis with a rabbit polyclonal antibody against P-gp. Intramolecular disulfide cross-linking between TMD1 and TMD2 can be detected due to slower mobility of cross-linked product on SDS-PAGE gels.

MOL #29926

Results

The first step was to compare various compounds for their efficiency in promoting maturation of P-gp and CFTR processing mutants. Compounds such as thapsigargin, curcumin (Egan et al., 2004), miglustat (Norez et al., 2006b) and benzo(c)quinolizinium compounds (Dormer et al., 2001) are predicted to promote maturation of membrane proteins such as $\Delta F508$ CFTR by disrupting protein-chaperone interactions in the endoplasmic reticulum. Cyclosporin A promotes maturation of P-gp processing mutants through direct interactions with the protein (Loo and Clarke, 1997) while an NH₂-terminal wild-type CFTR half-molecule was postulated to promote maturation of $\Delta F508$ CFTR through a direct transcomplementation interaction (Cornet-Boyaka et al., 2004). The ability of the various compounds and N-half molecules to promote maturation of $\Delta F508$ CFTR and the G268V P-gp processing mutants were compared with VRT-325 and corr-4a. VRT-325 was selected because it can promote maturation of CFTR or P-gp processing mutants whereas corr-4a is more specific for CFTR. The G268V P-gp processing mutant was used in the study as the protein shows a very low efficiency of maturation (Loo et al., 2005). Expression of P-gp and CFTR half-molecules was confirmed by immunoblot analysis (data not shown).

The G268V P-gp and $\Delta F508$ CFTR mutants were expressed in the presence of the various compounds for 24 h and whole cell extracts were subjected to immunoblot analysis. The mature and immature forms can be distinguished on SDS-PAGE gels because CFTR (Fig. 1A) and P-gp (Fig. 1B) contain 2 and 3 N-glycosylation sites respectively, that are core-glycosylated in the endoplasmic reticulum but are modified with complex carbohydrates if they are delivered to the Golgi. Fig. 2A shows that expression of $\Delta F508$ CFTR in HEK 293 cells yields little mature protein unless it is expressed in the presence of 10 μ M VRT-325 or 10 μ M corr-4a (Fig. 2B).

MOL #29926

Maturation of the P-gp processing mutant G268V was readily promoted by expression in the presence of VRT-325 and cyclosporin A (Fig. 2A). Therefore, VRT-325 was a particularly useful compound because it could promote maturation of both CFTR and P-gp. The next step was to examine which parts of the molecules were important for maturation (conversion of immature core-glycosylated protein to mature endoglycosidase H- resistant product).

CFTR and P-gp are members of the ATP-binding Cassette (ABC) family of transporters. These transporters have two TMDs and two NBDs (Fig. 1). CFTR also has a regulatory domain (Fig. 1A). Structural studies suggest that pharmacological chaperones may promote folding of CFTR or P-gp processing mutants by facilitating NBD1-NBD2 interactions and vectorial folding of NBD2 (Du et al., 2005) or by promoting folding of the TMDs (Chen et al., 2004; Loo and Clarke, 1999b). To test the importance of the NBDs for maturation, P-gp truncation mutants lacking NBD2 (Δ NBD2 P-gp) or both NBDs (TMD1+2 P-gp) are useful because both proteins are normally expressed as immature proteins (Fig. 3A and 3B, - lanes). Expression of Δ NBD2 P-gp (Fig. 3A) or TMD1+2 (P-gp) (Fig. 3B) in the presence of 10 μ M VRT-325 however, promoted maturation of the protein. We have previously demonstrated that the mature 120 kDa Δ NBD2 and 90 kDa TMD1+2 P-gp proteins were resistant to endoglycosidase H but sensitive to PNGase F and delivered to the cell surface (Loo and Clarke, 1999b).

To determine the minimum domain structure required for maturation, we tested the effect of VRT-325 on maturation of TMD1 P-gp or N-half P-gp as these two proteins are normally expressed as core-glycosylated proteins (Loo and Clarke, 1995). Maturation was not observed when TMD1 or N-half P-gps were expressed in the presence of 10 μ M VRT-325 (Fig. 3C). These results indicate that the minimum structure required for maturation of P-gp with VRT-325

MOL #29926

was the either two TMDs or one TMD and at least part of the second TMD. Interactions between the NBDs was not required to promote maturation of P-gp with VRT-325.

Some P-gp mutants are synthesized with an altered topology. For example, expression of P-gp C-half (COOH-terminal P-gp half-molecule) mutant E875C yielded a protein that becomes glycosylated at Asn 809 (Loo and Clarke, 1999a). Residue Asn 809 is not normally glycosylated because it is located on the cytoplasmic side of the membrane in the loop connecting TMs 8 and 9 (see Fig. 1B). The presence of the E875C mutation appears to disrupt folding so that TMs 8 and /or 9 are not properly inserted into the membrane. To test if VRT-325 could correct the topology, C-half E875C P-gp was expressed with or without N-half P-gp (NH₂-terminal P-gp half molecule) in the presence or absence of VRT-325. The C-half molecule contained an A52 epitope tag and glycosylation at Asn 809 was monitored by testing for sensitivity to endoglycosidase H. Fig. 3D shows that core-glycosylated C-half E875C P-gp could be detected when the protein was expressed with or without N-half P-gp or expressed by itself in the presence or absence of VRT-325. When C-half E875 P-gp was expressed in the presence of both N-half P-gp and VRT-325 however, core-glycosylated C-half P-gp expression was suppressed. These results suggest that expression of C-half E875C and N-half P-gps in the presence of VRT-325 promoted interactions between the two proteins to enhance the yield of C-half polypeptide that is not glycosylated.

VRT-325 may promote interactions between the two half-molecules of P-gp by interacting at the drug-binding domain. The drug-binding domain is located at the interface between the two TMDs (Loo et al., 2006a; Loo et al., 2006b). An approach to test whether VRT-325 can occupy the drug-binding domain is to determine if it will inhibit cross-linking between a cysteine in TMD2 (F728C in TM7) (Loo et al., 2006b) and a cysteine in TMD1 (L339C in TM6) (Loo and

MOL #29926

Clarke, 2001) (see Fig. 1B) predicted to lie on each side of the drug-binding domain. Disulfide cross-linking between cysteines in the TMDs can readily be detected as the cross-linked protein migrates slower on SDS-PAGE gels. Cross-linking can be inhibited in the presence of drug substrate (Loo et al., 2006b). Mutant L339C(TM6)/F728C(TM7) shows cross-linking when it is treated with the cross-linker M14M (Fig. 4, “None” lane). We tested different classes of corrector molecules such as corr-2b, corr-3a, corr-4a, corr-4b (Pedemonte et al., 2005), VRT-532 (Wang et al., 2006), and VRT-325 (Loo et al., 2005) for their abilities to inhibit cross-linking of L339C(TM6)/F728C(TM7). It was found that VRT-325 was the most potent inhibitor as reduced cross-linking was observed in the presence of 10 or 100 μ M VRT-325 (Fig. 4). Inhibition of cross-linking was also observed with 100 μ M corr-3a and corr-4b. No inhibition of cross-linking was observed with corr-2b, corr-4a or VRT-532. The results suggest that compounds corr-3a, corr-4b and VRT-325 can directly interact with P-gp. Although the correctors may block cross-linking through occupation of the drug-binding domain of P-gp, it cannot be ruled out that they bind at another site and cause distant conformational changes. It was previously shown that VRT-325, corr-3a and corr-4b, but not corr-2b, corr-4a or VRT-532 promoted maturation of the G268V P-gp processing mutant (Wang et al., 2006).

The next step was to test if NBD1-NBD2 interactions were essential for promotion of CFTR maturation with correctors. A CFTR cDNA lacking NBD2 (Δ NBD2 CFTR) was constructed and expressed in HEK 293 cells. CFTR was found to be different from P-gp because Δ NBD2 CFTR matured in the absence of correctors to yield an endoglycosidase H-resistant protein as the major product (Fig. 5A).

If correctors interact with NBD2 of CFTR to promote maturation, then they would have no effect on a Δ NBD2 processing mutant. To test if correctors could still promote maturation of a

MOL #29926

CFTR mutant lacking NBD2, we first needed to introduce a processing mutation into Δ NBD2 CFTR. Accordingly, the Q1071P processing mutation was introduced into the Δ NBD2 CFTR. The Q1071P processing mutation was selected because it is located in the fourth cytoplasmic loop (see Fig. 1B) and it was postulated to inhibit maturation because it disrupted NBD2-TMD2 interactions (Seibert et al., 1996). Since NBD2 is no longer present in Δ NBD2 CFTR, we can now test whether the Q1071P mutation would still inhibit maturation. It was found that the processing mutant Q1071P could still inhibit maturation of CFTR lacking NBD2 (Δ NBD2/Q1071P, Fig. 5B). Therefore, the Q1071P mutation appears to interfere in the folding of TMD2. Maturation of the Δ NBD2/Q1071P CFTR mutant could be promoted however, when expression was carried out in the presence of VRT-325 or corr-4a (Fig. 5B). The increase in maturation occurred in a concentration-dependent manner (Fig. 5C).

The conversion of Δ NBD2/Q1071P CFTR to an endoglycosidase H-resistant protein after expression in the presence of correctors indicates that it reached the Golgi. To determine if expression in the presence of correctors would increase the level of Δ NBD2/Q1071P at the plasma membrane, cell surface labeling was carried out. HEK 293 cells transfected with Δ NBD2/Q1071P cDNA containing an A52-epitope tag were expressed in the presence or absence of 10 μ M VRT-325 or corr-4a. The cells were treated with sodium periodate to oxidize carbohydrate groups and the oxidized carbohydrates were labeled with biotin-LC-hydrazide. CFTR was isolated by immunoprecipitation with A52 antibody and subjected to immunoblot analysis with horseradish peroxidase conjugated to streptavidin. Fig. 5D shows that cell surface expression of Δ NBD2/Q1071P was increased after expression in the presence of VRT-325 or corr-4a. A control immunoblot developed with monoclonal antibody A52 shows that similar levels of Δ NBD2/Q1071P protein were recovered after immunoprecipitation (Fig. 5E). CFTR

MOL #29926

protein expression of Δ NBD2 CFTR in stable BHK cells yielded functional cAMP-activated chloride channel activity in whole cell iodide efflux assays (data not shown). It has previously been reported that Δ NBD2 CFTR can form functional channels at the cell surface when expressed in a low temperature system (Chan et al., 1999).

To test if a CFTR lacking both NBDs could undergo maturation, a TMD1+2 CFTR mutant was constructed and then expressed in the presence or absence of 10 μ M VRT-325 or corr-4a. Whole cell extracts were treated with or without endoglycosidase H and then subjected to immunoblot analysis. In contrast to P-gp TMD1+2, CFTR TMD1+2 was inefficiently core-glycosylated (Fig. 6A, - lanes). Expression of CFTR TMD1+2 in the presence of VRT-325 or corr-4a however, enhanced core-glycosylation to yield about equal amounts of core-glycosylated and unglycosylated proteins (Fig. 6A, + lanes). The correctors appear to promote folding of the glycosylated loop between TM segments 7 and 8 in CFTR TMD1+2 to enhance the efficiency of glycosylation.

A C-half CFTR was then constructed to test the effects of correctors on glycosylation of CFTR missing the front half of the protein. When C-half CFTR was expressed in the absence of correctors, it was found that the protein was also inefficiently glycosylated (Fig. 6B). The C-half CFTR product yielded a mix of unglycosylated and core-glycosylated protein. Expression of C-half CFTR was then carried out in the presence or absence of 10 μ M VRT-325 or corr-4a. Immunoblot analysis showed that expression of C-half CFTR in the presence of correctors did not significantly enhance glycosylation of the protein (Fig. 6C).

MOL #29926

Discussion

This study shows that establishment of native interactions between the NBDs of CFTR or P-gp is not required for corrector-induced maturation of the proteins. Instead, it was found that the correctors could still influence the folding of P-gp or CFTR truncation mutants lacking both NBDs. Both TMDs were required as P-gp constructs containing only TMD1 (TMD1 or N-half P-gps) (Fig. 3) or CFTR constructs containing only TMD2 (C-half CFTR) (Fig. 6) showed no increase in maturation or increased efficiency in glycosylation when expressed in the presence of correctors. The observation that VRT-325 could block disulfide cross-linking between cysteines located in TM6(L339C) and TM7(F728C) (Fig. 4) suggested that there was direct interaction of the compound with P-gp. Since cysteines at positions 339(TM6) and 728(TM7) are predicted to line the drug-binding pocket, the ability of VRT-325 to block cross-linking would suggest that the compound occupies the drug-binding domain. It is possible however, that VRT-325 binds to a more distal site but affects cross-linking through long-range conformational changes.

The ability of VRT-325 to promote glycosylation of CFTR TMD1 + 2 and suppress aberrant glycosylation of E875C C-half P-gp provides a clue as to how correctors can aid in the folding process. They appear to be able to modulate the insertion of TM segments into the bilayer during synthesis. In the case of TMD1+2 CFTR, core-glycosylation was inefficient in the absence of corrector. Inefficient core-glycosylation of TMD1+2 CFTR suggests that the extracellular loop containing the two N-glycosylation sites (between TM segments 7 and 8) was not positioned correctly during synthesis of the protein in the absence of corrector. The acceptor sites for N-linked glycosylation must be 12-14 residues from the luminal ends of the TM segments (Nilsson and von Heijne, 1993). Apparently, expression of TMD1+2 CFTR in the presence of VRT-325 or corr-4a promoted insertion of TM segments 7 and 8 in an orientation so that the high-mannose

MOL #29926

oligosaccharide acceptor sites were in the lumen at a distance of 12-14 residues above the membrane. The problems with proper orientation of the glycosylated loop may involve TM8. TM8 of CFTR is unusual as it has poor stop translocation properties and removal of a negatively charged residue in TM8 (Asp 924) altered the topology of the extracellular loop between TM segments 7 and 8 (Carveth et al., 2002). Asp 924 normally forms a salt bridge with Arg 347 in TM6 of TMD1 (Cotten and Welsh, 1999). Core-glycosylation of P-gp TMD1+2 was much more efficient than CFTR TMD1+2. In addition, the TMD1+2 P-gp protein could undergo maturation when expressed in the presence of VRT-325. Therefore, insertion and orientation of P-gp TM segments may be more efficient than CFTR. Insertion and orientation of CFTR TM segments may be prone to errors because it has been shown that many of the TM segments have poor signal and stop-transfer determinants (Sadlish and Skach, 2004). This may be partly due to the large number (eleven) of charged residues in the TM segments that affects the stability of the TM segments in the bilayer. For example, in a study that used a truncation mutant consisting of the first quarter of the molecule (included TMs 1-6) it was shown that TM6 of CFTR, which has 3 positively charged residues, is very unstable in the lipid bilayer (Tector and Hartl, 1999). Insertion of P-gp TM segments into a proper orientation may be more efficient than CFTR because they do not contain any charged residues. Although P-gp may be more efficiently synthesized than CFTR to yield a native topology, it is not without problems. The C-half of P-gp can be synthesized with alternative topologies (Loo and Clarke, 1999a; Skach et al., 1993; Zhang and Ling, 1991). In addition, the E875C P-gp C-half mutant showed aberrant glycosylation that could be corrected upon expression in the presence of VRT-325.

A hydrophobic pharmacological chaperone may promote folding of CFTR and P-gp by interacting with the hydrophobic face of one or more TM segments to act as 'pharmacological

MOL #29926

anchor' to retain the unstable TM segments in the lipid bilayer. A model showing the alteration of the topologies of the P-gp E875C C-half mutant and CFTR TMD1+2 is shown in Fig. 7. Expression in the presence of a corrector enhances expression of a truncation mutant with a native topology.

CFTR was also found to be different from P-gp because Δ NBD2 CFTR matured in the absence of a pharmacological chaperone (Fig. 5). By contrast, Δ NBD2 P-gp is only synthesized as immature protein unless it is expressed in the presence of a drug substrate such as cyclosporin A (Loo and Clarke, 1999b). In agreement with Chan et al. (Chan et al., 1999), we found that Δ NBD2 CFTR formed functional channels at the cell surface (data not shown). It has been found however, that the number of amino acids deleted in NBD2 and their locations can greatly influence maturation and activity of the protein. For example, a Δ NBD2 CFTR mutant lacking amino acids 1185-1349 did not mature in HEK 293 cells (Zerhusen and Ma, 1999). Channel measurements on microsomal membranes, however, showed that the mutant was active. By contrast, deletion of residues 1165-1450 of NBD2 yielded mature protein when expressed in COS-1 cells but no channel activity could be detected (Pollet et al., 2000). A small deletion of only the last 65 amino acids of CFTR will inhibit maturation while CFTR containing a deletion of 200 amino acids could mature and yield functional channels at the cell surface (Gentsch and Riordan, 2001). It is possible that some of the COOH-terminal ends of the NBD2 CFTR truncation mutants are unstructured and may interfere with folding of the remainder of the protein. It is apparent however that NBD1-NBD2 or NBD2-TMD2 interactions are not essential for rescue with VRT-325 or corr-4a as both compounds could promote maturation of Δ NBD2/Q1071P CFTR.

MOL #29926

A second difference between P-gp and CFTR was that TMD1+2 P-gp can leave the endoplasmic reticulum for addition of complex carbohydrate but CFTR TMD1+2 did not. One reason may be that CFTR requires a COP II signal that is located in NBD1 to leave the endoplasmic reticulum (Wang et al., 2004). This signal is missing in TMD1+2 CFTR.

We have now observed that VRT-325 can affect folding of CFTR processing mutants in two ways. First, it can induce TMD1-TMD2 interactions in partially folded CFTR processing mutants to promote TM packing to yield a native conformation (Loo et al., 2006c). Secondly, VRT-325 can modulate insertion of TM segments to yield segments that are properly oriented in the lipid bilayer. Compounds such as VRT-325 and corr-4a were more efficient than other approaches such as transcomplementation or disruption of CFTR-chaperone interactions with compounds such as thapsigargin, curcumin or miglustat in promoting maturation of Δ F508 CFTR. Compounds such as thapsigargin, curcumin and miglustat that are postulated to modulate CFTR-chaperone interactions, however, have been reported to be most effective with short incubation periods of 2 h (Norez et al., 2006a). Transcomplementation of Δ F508 CFTR or Δ Y490 P-gp with their respective N-half wild-type polypeptides did not yield detectable levels of full-length protein (Fig. 2A). In the original transcomplementation studies (Cormet-Boyaka et al., 2004) it was reported that different cell lines and expression systems influenced the yield of mature CFTR. The efficiency of maturation is very low when transcomplementation studies with Δ F508 CFTR were performed in HEK 293 cells but very efficient in vaccine-infected COS-7 cells (Cormet-Boyaka et al., 2004).

In conclusion, VRT-325 is a useful compound to promote maturation of CFTR as it promotes packing of the TM segments between TMD1 and TMD2 of CFTR and can enhance the insertion of TM segments in the correct orientation in the lipid bilayer.

MOL #29926

Acknowledgments

We thank the Cystic Fibrosis Foundation (U.S.A.) and Vertex Corporation (San Diego, CA) for providing VRT-325 and VRT-532. We thank Dr. Robert Bridges (Rosalind Franklin University) and the Cystic Fibrosis Foundation Therapeutics Inc. for samples of VRT-325 and corr-4a.

MOL #29926

References

- Bobadilla JL, Macek M, Jr., Fine JP and Farrell PM (2002) Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. *Hum Mutat* **19**:575-606.
- Carveth K, Buck T, Anthony V and Skach WR (2002) Cooperativity and flexibility of cystic fibrosis transmembrane conductance regulator transmembrane segments participate in membrane localization of a charged residue. *J Biol Chem* **277**:39507-39514.
- Chan KW, Csanady L, Nairn AC and Gadsby DC (1999) Deletion analysis of CFTR channel R domain using severed molecules. *Biophys J*:A405.
- Chen EY, Bartlett MC and Clarke DM (2000) Cystic fibrosis transmembrane conductance regulator has an altered structure when its maturation is inhibited. *Biochemistry* **39**:3797-3803.
- Chen EY, Bartlett MC, Loo TW and Clarke DM (2004) The Δ F508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator. *J Biol Chem* **279**:39620-39627.
- Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR and Smith AE (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. *Cell* **63**:827-834.
- Cornet-Boyaka E, Jablonsky M, Naren AP, Jackson PL, Muccio DD and Kirk KL (2004) Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation. *Proc Natl Acad Sci U S A* **101**:8221-8226.

MOL #29926

Cotten JF and Welsh MJ (1999) Cystic fibrosis-associated mutations at arginine 347 alter the pore architecture of CFTR. Evidence for disruption of a salt bridge. *J Biol Chem* **274**:5429-5435.

Dormer RL, Derand R, McNeilly CM, Mettey Y, Bulteau-Pignoux L, Metaye T, Vierfond JM, Gray MA, Galiotta LJ, Morris MR, Pereira MM, Doull IJ, Becq F and McPherson MA (2001) Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. *J Cell Sci* **114**:4073-4081.

Du K, Sharma M and Lukacs GL (2005) The Δ F508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. *Nat Struct Mol Biol* **12**:17-25.

Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, Canny S, Du K, Lukacs GL and Caplan MJ (2004) Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. *Science* **304**:600-602.

Gentsch M and Riordan JR (2001) Localization of sequences within the C-terminal domain of the cystic fibrosis transmembrane conductance regulator which impact maturation and stability. *J Biol Chem* **276**:1291-1298.

Hoof T, Demmer A, Hadam MR, Riordan JR and Tummeler B (1994) Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1. *J Biol Chem* **269**:20575-20583.

Lewis HA, Zhao X, Wang C, Sauder JM, Rooney I, Noland BW, Lorimer D, Kearins MC, Connors K, Condon B, Maloney PC, Guggino WB, Hunt JF and Emtage S (2005) Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis

MOL #29926

transmembrane conductance regulator on domain folding and structure. *J Biol Chem* **280**:1346-1353.

Loo TW, Bartlett MC and Clarke DM (2002) Introduction of the Most Common Cystic Fibrosis Mutation (Δ F508) into Human P-glycoprotein Disrupts Packing of the Transmembrane Segments. *J Biol Chem* **277**:27585-27588.

Loo TW, Bartlett MC and Clarke DM (2005) Rescue of Δ F508 and other misprocessed CFTR mutants by a novel quinazoline compound. *Mol Pharm* **2**:407-413.

Loo TW, Bartlett MC and Clarke DM (2006a) Transmembrane segment 1 of human P-glycoprotein contributes to the drug binding pocket. *Biochem J* **396**:537-545.

Loo TW, Bartlett MC and Clarke DM (2006b) Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. *Biochem J* **399**:351-359.

Loo TW, Bartlett MC, Wang Y and Clarke DM (2006c) The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR processing mutants. *Biochem J* **395**:537-542.

Loo TW and Clarke DM (1995) P-glycoprotein. Associations between domains and between domains and molecular chaperones. *J Biol Chem* **270**:21839-21844.

Loo TW and Clarke DM (1997) Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. *J Biol Chem* **272**:709-712.

Loo TW and Clarke DM (1999a) The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates. *Biochemistry* **38**:5124-5129.

MOL #29926

Loo TW and Clarke DM (1999b) The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. *J Biol Chem* **274**:24759-24765.

Loo TW and Clarke DM (2001) Defining the drug-binding site in the human multidrug resistance P-glycoprotein using MTS-verapamil. *J Biol Chem* **276**:14972-14979.

Nilsson IM and von Heijne G (1993) Determination of the distance between the oligosaccharyltransferase active site and the endoplasmic reticulum membrane. *J Biol Chem* **268**:5798-5801.

Norez C, Antigny F, Becq F and Vandebrouck C (2006a) Maintaining low Ca²⁺ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells. *Traffic* **7**:562-573.

Norez C, Noel S, Wilke M, Bijvelds M, Jorna H, Melin P, DeJonge H and Becq F (2006b) Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. *FEBS Lett* **580**:2081-2086.

Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galiotta LJ and Verkman AS (2005) Small-molecule correctors of defective Δ F508-CFTR cellular processing identified by high-throughput screening. *J Clin Invest* **115**:2564-2571.

Pollet JF, Van Geffel J, Van Stevens E, Van Geffel R, Beauwens R, Bollen A and Jacobs P (2000) Expression and intracellular processing of chimeric and mutant CFTR molecules. *Biochim Biophys Acta* **1500**:59-69.

Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, Drumm ML, Iannuzzi MC, Collins FS and Tsui L-C (1989)

MOL #29926

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* **245**:1066-1073.

Sadlish H and Skach WR (2004) Biogenesis of CFTR and other polytopic membrane proteins: new roles for the ribosome-translocon complex. *J Membr Biol* **202**:115-126.

Seibert FS, Linsdell P, Loo TW, Hanrahan JW, Clarke DM and Riordan JR (1996) Disease-associated mutations in the fourth cytoplasmic loop of cystic fibrosis transmembrane conductance regulator compromise biosynthetic processing and chloride channel activity. *J Biol Chem* **271**:15139-15145.

Skach WR, Calayag MC and Lingappa VR (1993) Evidence for an alternate model of human P-glycoprotein structure and biogenesis. *J Biol Chem* **268**(10):6903-6908.

Smith PC, Karpowich N, Millen L, Moody JE, Rosen J, Thomas PJ and Hunt JF (2002) ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. *Mol Cell* **10**:139-149.

Tector M and Hartl FU (1999) An unstable transmembrane segment in the cystic fibrosis transmembrane conductance regulator. *Embo J* **18**:6290-6298.

Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, Neuberger T, Olson E, Panchenko V, Rader J, Singh A, Stack JH, Tung R, Grootenhuis PD and Negulescu P (2006) Rescue of $\Delta F508$ CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. *Am J Physiol Lung Cell Mol Physiol* **290**:L1117-1130.

Wang X, Matteson J, An Y, Moyer B, Yoo JS, Bannykh S, Wilson IA, Riordan JR and Balch WE (2004) COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code. *J Cell Biol* **167**:65-74.

MOL #29926

Wang Y, Bartlett MC, Loo TW and Clarke DM (2006) Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. *Mol Pharmacol* **70**:297-302.

Zerhusen B and Ma J (1999) Function of the second nucleotide-binding fold in the CFTR chloride channel. *FEBS Lett* **459**:177-185.

Zhang JT and Ling V (1991) Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation. *J Biol Chem* **266**:18224-18232.

MOL #29926

Footnotes

This work was supported by a grant from the Canadian Institutes of Health Research and a grant from the National Cancer Institute of Canada through the Canadian Cancer Society. DMC is the recipient of the Canada Research Chair in Membrane Biology.

MOL #29926

FIGURE LEGENDS

Fig. 1. Models of CFTR and P-gp. The cylinders represent TM segments, the glycosylation sites are represented by branched lines and R represents the R domain. The CFTR models (A) of full-length CFTR (residues 1-1480), Δ NBD2 CFTR (residues 1-1023), TMD1+2 CFTR (residues 1-438 plus 838-1178) and C-half CFTR (residues 837-1480) are shown. The position of the Q1071P mutation in Δ NBD2 CFTR is indicated. For P-gp (B), the filled circles in full-length P-gp (residues 1-1280) represent the locations of processing mutations examined in this study. The open square represents an N-glycosylation site that is not modified in wild-type P-gp. The filled boxes represent sites in the TMDs that were used in disulfide cross-linking analysis. The models of Δ NBD2 P-gp (residues 1-1023), TMD1+2 (residues 1-379 plus 681-1025), TMD1 P-gp (residues 1-379) and N-half P-gp (residues 1-682) truncation mutants are shown.

Fig. 2. Effects of compounds or transcomplementation on maturation of P-gp and CFTR processing mutants. (A) HEK 293 cells were transfected with cDNAs for Δ F508 CFTR or G268V P-gp, co-transfected with NH₂-terminal half-molecule (N-half mol) derived from wild-type CFTR or P-gp. Cells were then incubated for 24 h in the presence of 10 μ M VRT-325, 10 μ M corr-4a, 10 μ M curcumin, 250 μ M 7,8-benzoquinoline (benzoquinone), 100 μ M miglustat, 10 μ M thapsigargin (thapsigarg), 10 μ M cyclosporin A (Cyclo A) or 0.1% (v/v) DMSO (None). Whole cell extracts were then subjected to immunoblot analysis. The positions of mature and immature CFTR or P-gp are indicated. The structures of VRT-325 and corr-4a are also shown (B).

MOL #29926

Fig. 3. Effect of VRT-325 on maturation of P-gp truncation mutants. A52-tagged P-gp mutants lacking NBD2 (Δ NBD2 P-gp) (A), missing both NBDs (TMD1+2) (B), missing the back half (N-Half) or missing the last three quarters of the molecule (TMD1) (C) were expressed for 24 h in the presence (+) or absence (-) of 10 μ M VRT-325. Equivalent amounts of whole cell SDS extracts were subjected to immunoblot analysis. The positions of mature and immature proteins are indicated. (D) HEK 293 cells were transfected with C-half/ E875C P-gp with (+) or without (-) N-half P-gp and then incubated for 24 h in the presence (+) or absence (-) of 10 μ M VRT-325. Whole cell extracts were treated with (+) or without (-) endoglycosidase H and subjected to immunoblot analysis with monoclonal antibody A52. The positions of the core-glycosylated (Core) and unglycosylated (Unglycos) C-half proteins are indicated.

Fig. 4. Effect of corrector molecules on disulfide cross-linking of P-gp mutant L339C(TM 6)/F728C(TM7). Membranes were prepared from HEK 293 cells transfected with P-gp L339C (TM 6)/ F728C(TM7) cDNA and then incubated at 22 °C for 15 min in the presence of 0.1 mM (a) or 0.01 mM (b) corr-2b, corr-3a, corr-4a, corr-4b, VRT-532, VRT-325 or no corrector (None). Samples were then cooled on ice and treated with (+) or without (-) M14M cross-linker on ice for 3 min. The reactions were stopped by addition of SDS sample buffer and samples were subjected to immunoblot analysis. The positions of mature (170 kDa) and cross-linked (X-link) P-gps are indicated.

Fig. 5. Effects of VRT-325 and corr-4a on maturation of CFTR truncation mutants. (A) Whole cell extracts of HEK 293 cells transfected with A52-tagged Δ NBD2 CFTR cDNA were treated with endoglycosidase H (H), PNGase F (F) or untreated (-). Samples were then subjected to

MOL #29926

immunoblot analysis with monoclonal antibody A52. (B) CFTR truncation mutants Δ NBD2 CFTR or Δ NBD2/Q1071P containing C-terminal A52 tags were expressed in the presence of 10 μ M VRT-325 (325) or 10 μ M corr-4a or no corrector (-) for 24 h. Whole cell extracts were then subjected to immunoblot analysis with monoclonal antibody A52. (C) The concentration dependence of maturation of Δ NBD2/Q1071P CFTR was determined by expressing the mutant in the indicated concentrations of corr-4a (4a) for 24 h followed by immunoblot analysis of whole cell extracts. (D) HEK 293 cells transfected with A52-tagged Δ NBD2/Q1071P CFTR cDNA were grown in the presence (+) or absence (-) of 10 μ M VRT-325 (325) or 10 μ M corr-4a (4a) for 24 h. Cell surface labeling was then performed on whole cells using biotin-LC-hydrazide after oxidation of surface carbohydrates. Biotinylated CFTR was immunoprecipitated using monoclonal antibody A52 and samples were subjected to immunoblot analysis using streptavidin-conjugated horseradish peroxidase. The positions of mature (Mature) and immature (Immature) CFTR proteins are indicated. (E) Samples from the immunoprecipitation experiments and that from untransfected cells (Con) were subjected to immunoblot analysis with A52 monoclonal antibody.

Fig. 6. Effect of VRT-325 or corr-4a on glycosylation of C-half or TMD1+2 CFTRs. (A) A52-tagged TMD1+2 CFTR was expressed in the presence of 10 μ M VRT-325 (325, +), 10 μ M corr-4a (4a, +) or no corrector (-) for 24 h. Whole cell extracts were subjected to immunoblot analysis with monoclonal antibody A52. Some samples from cells treated with corrector were treated with endoglycosidase H (+/H). (B) Whole cell extracts of HEK 293 cells transfected with C-half CFTR cDNA and incubated in the absence of correctors were treated with (+) or without (-) endoglycosidase H (H) or PNGase F (F) followed by immunoblot analysis with monoclonal


MOL #29926

antibody A52. (C) HEK 293 cells transfected with C-half CFTR were incubated in the presence of 10 μ M VRT-325 (325) or corr-4a (4a) for 24 h. Whole cell extracts were then subjected to immunoblot analysis with monoclonal antibody A52. The positions of core-glycosylated (Core) and unglycosylated (Unglycos) CFTR proteins are indicated.


Fig. 7. Models of altered topologies of P-gp and CFTR. The cylinders represent TM segments while the branched lines represent glycosylation sites. (A) P-gp mutant E875C shows increased expression of a C-half polypeptide that is glycosylated at Asn 809 (N809) (Altered). Therefore, TM segments 8 and/or 9 must not be properly orientated in the membrane. Expression of C-half E875C in the presence of wild-type N-half P-gp and VRT-325 (+ corrector) enhances the relative level of C-half polypeptide with a native topology (Normal). Disulfide cross-linking analysis suggests that VRT-325 (grey oval) can directly interact with TM segments. It may act as a pharmacological anchor to select for a relative topology. (B) TMD1+2 CFTR is not efficiently glycosylated at the native Asn 894 (N894) and Asn 900 (N900) sites when expressed in the absence of correctors which suggests that TMs 8 and/or 9 are not correctly orientated in the membrane (Altered). Expression of TM1+2 in the presence of correctors (grey oval) reorients TM 8 and/or 9 into a native topology that can be core-glycosylated (Normal). Correctors may interact with one or more TM segments.

A


Full-length CFTR




Δ NBD2 CFTR



TMD 1+2 CFTR



C-Half CFTR




Molecular Pharmacology Fast Forward. Published on November 28, 2016 as DOI: 10.1124/mol.106.02926
This article has not been copyedited and formatted. The final version may differ from this version.


Downloaded from molpharm.aphpharmsoc.org at ASHET Journals on April 16, 2024

Fig. 1A


B Full-length P-gp




Δ NBD2 P-gp




TMD 1+2 P-gp



TMD1 P-gp




N-Half P-gp



Molecular Pharmacology Fast Forward. Published on November 28, 2006 as DOI: 10.1124/mol.106.02926
This article has not been copyedited and formatted. The final version may differ from this version.


Downloaded from molpharm.asphpubs.org at ASHET Journals on April 19, 2024



Molecular Pharmacology Fast Forward. Published on November 28, 2006 as DOI: 10.1124/mol.106.02926
This article has not been certified and formatted. The final version may differ from this version.


10.1124/mol.106.02926

Fig. 2A



Corr-4a:

N-[2-(5-chloro-2-methoxy-phenylamino)-4'-methyl-[4,5'] bithiazolyl-2'-yl]-benzamide







Molecular Pharmacology Fast Forward. Published on November 28, 2016 as DOI: 10.1124/mol.106.02926
This article has not been certified and formatted. The final version may differ from this version.

VRT-325 (CFcor-325):

4-cyclohexyloxy-2-{1-[4-(4-methoxy-benzenesulfonyl)-piperazin-1-yl]-ethyl}-quinazoline

Downloaded from https://www.aspetjournals.org/ at ASPET Journals on April 16, 2024

A**B****C****D**








Fig. 4



Molecular Pharmacology Fast Forward. Published on November 28, 2006 as DOI: 10.1124/mol.106.02926
This article has not been certified and formatted. The final version may differ from this version.

DOI: 10.1124/mol.106.02926

Fig. 5


A**B****C**

Molecular Pharmacology Fast Forward. Published on November 28, 2006 as DOI: 10.1124/mol.106.02926
This article has not been certified and formatted. The final version may differ from this version.

Downloaded from molpharm.aphpharmsoc.org at ASHET Journals on April 19, 2024

Fig. 6

A) P-gp



B) CFTR

